<p dir="rtl" style="text-align: left;">Karcinom bronha je važna i &scaron;iroko rasprostranjena bolest koja predstavlja veliki problem javnog zdravlja. Kod osoba mu&scaron;kog pola se nalazi na prvom mestu kako po učestalosti obolevanja tako i kao uzrok smrti među svim malignim tumorima, dok se kod osoba ženskog pola nalazi na trećem ili četvrtom mestu po obolevanju, a po umiranju uglavnom na drugom mestu. Kod najvećeg broja bolesnika bolest se otkriva u uznapredovalom ili metatstaskom stadijumu, a hemioterapija predstavlja jedan od vidova lečenja uznapredovale ili metastatske bolesti. Pored toga &scaron;to produžava preživljavanje i pobolj&scaron;ava kvalitet života obolelih praćena je istovremeno i brojnim neželjenim događajima. Iako hemioterapijski protokoli bazirani na preparatima platine ostvaruju najveću efektivnost kod bolesnika sa uznapredovalim nemikrocelularnim karcinomom bronha toksičnost koja je prati predstavlja najveći problem sa kojim se susrećemo. Ali, uprkos ovoj činjenici veliki broj studija je pokazao da je upravo odsustvo mijelotoksičnosti tokom hemioterapije udruženo sa lo&scaron;ijim ishodom lečenja kod obolelih od karcinoma bronha. Iz tog razloga je i predloženo da se hematolo&scaron;ka toksičnost koristi kao mera biolo&scaron;ke aktivnosti citotoksičnih lekova, njen prognostički značaj je evaluiran i proučavan u velikom broju studija. Ciljevi ove doktorske disertacije su bili da se utvrditi uticaj leukopenije, anemije i trombocitopenije kao nezavisnih prognostičkih faktora na preživljavanje bolesnika sa nemikrocelularnim karcinomom bronha; da se utvrditi učestalost hematolo&scaron;ke toksičnosti lečenih hemioterapijskim protokolima Cisplatin/Vepezid i Gemcitabin/Cisplatin i da se utvrdite razlike u preživljavanju bolesnika lečenih hemioterapijskim protokolima Cisplatin/Vepezid i Gemcitabin/Cisplatin. U uzorku je analizirano 200 bolesnika, 76% mu&scaron;kog i 24% ženskog pola, prosečne starosti 61.4 godine. Najzastupljenji su bili bolesnici u IV stadijumu 50.5%, a najče&scaron;ći patohistolo&scaron;ki tip karcinoma u uzorku je bio adenokarcinom sa 51.5%. Nije utvrđeno postojanje statistički značajne razlike u gradusima leukopenije, anemije i trombocitopenije između posmatranih grupa, (<em>X</em>²=2.908, <em>X</em>²=2.264, <em>X</em>²=3.403, p&gt;0.05). U obe grupe je univarijantnom analizom dokazanao da stadijum bolesti i terapijski odgovor imaju statistički značaj kao &bdquo;ne - hematolo&scaron;ki&ldquo; prognostički faktori (p&lt;0.01). U obe grupe su takođe univarijentnom analizom leukopenija, anemija i trombocitopenija identifikovane kao prognostički faktori kod obolelih od NSCLC, dok multivarijantnom analizom ni jedan od analiziranih faktora nije identifikovan kao prognostički. U obe grupe su bolesnici sa leukopenijom, anemijom i trombocitopenijom gradusa 3 i 4 imali statistički značajno duže preživljavanje u odnosu na bolesnike sa gradusom 0. Nije postojala razlika u preživljavanju bolesnika lečenih hemioterapijskim protokolima cisplatin/etopozid I gemcitabin/cisplatin (F=0.069; p&gt;0.05). Nije postojala razlika u preživljavanju bolesnika sa anemijom, leukopenijom i trombocitopenijom između grupa A i B za graduse 0, 3 i 4</p> / <p>Lung cancer is an important and widespread disease which represents a major public health problem. It is the most frequent disease among all malignant diseases at males, among women it is on the third or fourth place among malignant diseases. In most cases the disease is detected at an advanced or metastatic stage and chemotherapy is one of the therapy options of. Despite the fact that chemotherapy prolongs survival and improves quality of life of patients, at the same time chemotherapy causes a number of different adverse events. Although chemotherapy protocols based platinum achieve maximum effectiveness in patients with advanced non-small cell lung cancer, toxicity that accompanies represents a big problem. But despite this fact, a number of studies have shown that the absence of myelotoxicity during chemotherapy is associated with poorer treatment outcomes in patients with bronchial carcinoma. For this reason, it is proposed that hematological toxicity may be used as a measure of the biological activity of the cytotoxic drug, and its prognostic significance was studied and evaluated in a number of studies. The objectives of this dissertation were to determine the effect of leucopenia, anemia andthrombocytopenia as an independent prognostic factor in the survival of patients with Non Small Cell Lung lung cancer, to determine the incidence of hematological toxicity treated with chemotherapy protocols cisplatin/etoposid and gemcitabine/cisplatin and to determine differences in survival patients treated with chemotherapy protocols cisplatin/etoposid and gemcitabine/ cisplatin. We analyzed 200 patients, 76% male and 24% female, mean age 61.4 years. The most frequent were patients in stage IV 50.5%, and the most common histopathological type was adenocarcinoma with 51.5%. We did not find statistically significant differences in grade of leukopenia, anemia and thrombocytopenia between the groups (<em>X</em>²=2.908,<em> X</em>²=2.264, <em>X</em>²=3.403, p&gt;0.05). In both groups, the univariant analysis has shown that the stage of disease and response rate as a non-hematological prognostic factor had statistical significance (p &lt;0.01). In both groups of patients with NSCLC leucopenia, anemia and trombocitopenia has identified with univariant analysis as a prognostic factors, but multivariant analysis did not show that any of analyzed factors are prognostic. In both groups, patients with grade 3 and 4 of leucopenia, anemia and trombocitopenia had statistically longer survival than patients with grade 0. We did not find statistically significant difference in overall survival of patients treated with cisplatin/etoposid i gemcitabin/cisplatin regimes (F=0.069; p&gt;0.05). We did not find any statistically differences in overall survival between group A and B for leucopenia, anemia and trombocitopenia grade 0, 3 and 4.</p>

<p>U&nbsp; ovoj&nbsp; doktorskoj&nbsp; disertaciji&nbsp; sintetisane&nbsp; su&nbsp; dve&nbsp; različite&nbsp; klase jonskih&nbsp; tečnosti,&nbsp; na&nbsp; bazi&nbsp; imidazolijuma&nbsp; i&nbsp; holinijuma,&nbsp; sa&nbsp; ciljem snižavanja&nbsp; toksičnosti.&nbsp; Imidazolijumove&nbsp; jonske&nbsp; tečnosti&nbsp; su funkcionalizovane&nbsp; hidroksilnom&nbsp; i&nbsp; etarskom&nbsp; grupom&nbsp; u&nbsp; bočnom lancu. Uspe&scaron;nost sinteza jonskih tečnosti potvrđena je&nbsp; snimanjem IC&nbsp; i&nbsp; NMR&nbsp; spektara.&nbsp; Izmerene&nbsp; su&nbsp; gustine,&nbsp; viskoznosti&nbsp; i provodljivosti&nbsp; čistih&nbsp; imidazolijumovih&nbsp; i&nbsp; holinijumskih&nbsp; jonskih tečnosti.&nbsp; Na&nbsp; osnovu&nbsp; dobijenih&nbsp; eksperimentalnih&nbsp; rezultata,potpomognutim&nbsp; računarskim&nbsp; simulacijama&nbsp; diskutovana&nbsp; je strukturna organizacija između katjona i anjona. Utvrđeno je da prisustvo&nbsp; hidroksilne&nbsp; grupe&nbsp; u&nbsp; bočnom&nbsp; lancu&nbsp; imidazolovog katjona,&nbsp; značajno&nbsp; utiče&nbsp; na&nbsp; lokaciju&nbsp; anjona&nbsp; i&nbsp; samim&nbsp; tim&nbsp; na makroskopska&nbsp; svojstva.&nbsp; U&nbsp; nastavku&nbsp; su&nbsp; izmerene&nbsp; gustine&nbsp; i viskoznosti&nbsp; vodenih&nbsp; rastvora&nbsp; sa&nbsp; ciljem&nbsp; dobijanja&nbsp; informacija&nbsp; o uticaju&nbsp; dodatka&nbsp; holinijumskih&nbsp; i&nbsp; imidazolijumovih&nbsp; jonskih tečnosti&nbsp; na&nbsp; strukturu&nbsp; vode.&nbsp; Na&nbsp; osnovu&nbsp; B&nbsp; koeficijenta&nbsp; iz<br />viskoznosti,&nbsp; ekspanzibilnosti&nbsp; i&nbsp; rezultata&nbsp; simulacija&nbsp; molekulske dinamike,&nbsp; utvrđeno&nbsp; je&nbsp; da&nbsp; sve&nbsp; jonske&nbsp; tečnosti&nbsp; imaju&nbsp; structure making&nbsp; osobine.&nbsp; Takođe,&nbsp; na&nbsp; osnovu&nbsp; izračunatih&nbsp; specifičnih molarnih zapremina i doking analize na receptoru za gorak ukus,<br />ustanovljeno je da vodeni rastvori holinijumskih jonskih tečnosti imaju gorak ukus.<br />Toksičnost funkcionalizovanih imidazolijumovih jonskih tečnosti ispitana je na&nbsp; nekoliko biljnih vrsta&nbsp; (p&scaron;enica, ječam i krastavac), kao i na larvama&nbsp; <em>A.&nbsp; salina</em>&nbsp; i ćelijskoj liniji MRC-5. Potvrđeno jeda&nbsp; uvođenje&nbsp; hidroksilne&nbsp; grupe&nbsp; u&nbsp; alkil&nbsp; niz&nbsp; najvi&scaron;e&nbsp; se&nbsp; redukuju<br />toksičnosti&nbsp; imidazolijumovih&nbsp; jonskih&nbsp; tečnosti,&nbsp; dok&nbsp; je&nbsp; uticaj etarske&nbsp; grupe&nbsp; na&nbsp; smanjenje&nbsp; toksičnosti&nbsp; značajno&nbsp; manji. Ispitivanje&nbsp; citotoksičnosti&nbsp; i&nbsp; antibakterijske&nbsp; aktivnosti&nbsp; ukazalo&nbsp; je da holinijumske jonske tečnosti se mogu smatrati netoksičnima, i<br />pokazuju&nbsp; beningnije&nbsp; dejstvo&nbsp; u&nbsp; poređenju&nbsp; sa&nbsp; njihovim&nbsp; polaznim komponentama&nbsp; (askorbinska&nbsp; kiselina,&nbsp; biotin&nbsp; i&nbsp; nikotinska kiselina).</p> / <p><!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:PunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:DontVertAlignCellWithSp/> <w:DontBreakConstrainedForcedTables/> <w:DontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="&#45;-"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument></xml><![endif]--><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */ table.MsoNormalTable{mso-style-name:"Table Normal";mso-tstyle-rowband-size:0;mso-tstyle-colband-size:0;mso-style-noshow:yes;mso-style-priority:99;mso-style-qformat:yes;mso-style-parent:"";mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-para-margin-top:0in;mso-para-margin-right:0in;mso-para-margin-bottom:10.0pt;mso-para-margin-left:0in;line-height:115%;mso-pagination:widow-orphan;font-size:11.0pt;font-family:"Calibri","sans-serif";mso-ascii-font-family:Calibri;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:"Times New Roman";mso-bidi-theme-font:minor-bidi;}</style><![endif]--></p><p class="MsoNormal">In&nbsp; this&nbsp; doctoral&nbsp; thesis,&nbsp; ionic&nbsp; liquids&nbsp; based&nbsp; on&nbsp; imidazolium&nbsp; and cholinium cation were synthesized, in order to obtain new class of ILs with reduced toxicity. Imidazolium based ionic liquids were functionalized&nbsp; with hydroxyl and ether&nbsp; group in &nbsp; order to reduce their&nbsp; lipophilicity.&nbsp; All&nbsp; newly&nbsp; synthesized&nbsp; compounds&nbsp; were&nbsp; confirmed&nbsp; by&nbsp; measuring&nbsp; IR&nbsp; and&nbsp; NMR&nbsp; spectra.&nbsp; For&nbsp; pure&nbsp; ionic&nbsp; liquids, density, conductivity and viscosity were measured. Based on&nbsp; the&nbsp; obtained&nbsp; experimental&nbsp; results&nbsp; supported&nbsp; with&nbsp; results&nbsp; of&nbsp; molecular simulations, it was concluded that presence of oxygen in&nbsp; alkyl&nbsp; side&nbsp; chain&nbsp; of&nbsp; imidazolium&nbsp; ionic&nbsp; liquids&nbsp; significantly contribute to position of anion. Further,&nbsp; density&nbsp; and&nbsp; viscosity&nbsp; of&nbsp; diluted&nbsp; aqueous&nbsp; ILs&nbsp; solutions were&nbsp; measured&nbsp; with&nbsp; a&nbsp; purpose&nbsp; to&nbsp; investigate&nbsp; their&nbsp; influence&nbsp; on water&nbsp; structure.&nbsp; Based&nbsp; on&nbsp; obtained&nbsp; values&nbsp; for&nbsp; viscosicty&nbsp; B coefficient,&nbsp; expansibility&nbsp; and&nbsp; from&nbsp; MD&nbsp; simulations,&nbsp; all&nbsp; ionic&nbsp; liquids&nbsp; express&nbsp; structure&nbsp; making&nbsp; tendency.&nbsp; From&nbsp; calculated specific&nbsp; apparent&nbsp; molar&nbsp; volumes&nbsp; for&nbsp; cholinium&nbsp; ionic&nbsp; liquids&nbsp; it was noted bitter taste.&nbsp; The&nbsp; toxicity&nbsp; of&nbsp; functionalized&nbsp; imidazolium&nbsp; ionic&nbsp; liquids&nbsp; was investigated&nbsp; on&nbsp; different&nbsp; plant&nbsp; species&nbsp; (wheat ,&nbsp; barley&nbsp; and cucumber),&nbsp; on&nbsp; larvae&nbsp; of&nbsp;<em><span style="font-family:&quot;Calibri&quot;,&quot;sans-serif&quot;;mso-ascii-theme-font:minor-latin;mso-hansi-theme-font:minor-latin;mso-bidi-font-family:&quot;Times New Roman&quot;;mso-bidi-theme-font:minor-bidi"> A.&nbsp; salina</span></em>&nbsp; and&nbsp; cell&nbsp; line&nbsp; MRC-5.&nbsp; From<br />obtained&nbsp; results&nbsp; it&nbsp; was&nbsp; concluded&nbsp; that&nbsp; introduction&nbsp; of&nbsp; hydroxyl group in alkyl side chain reduce toxicity significantly more than&nbsp; ether&nbsp; group.&nbsp; Experiments&nbsp; on&nbsp; cytotoxicicity&nbsp; and&nbsp; antibacterial effects&nbsp; allowed&nbsp; to&nbsp; conclude&nbsp; that&nbsp; those&nbsp; newly&nbsp; synthesized cholinium ionic liquids can be considered as non-toxic.</p>

<p>Hemioterapija koja se koristi za lečenje karcinoma utiče i na kardiovaskularni sistem. Ciljevi&nbsp; istraživanja&nbsp; su: u tvrditi uticaj kardiotoksičnosti&nbsp; na&nbsp; reživljavanje&nbsp; bolesnika&nbsp; sa uznapredovalim stadijumom NSCLC; utvrditi učestalost pojave kardiotoksičnosti kod bolesnika koji su lečeni hemioterapijom prve linije (gemcitabin/cisplatin i paclitaxel/carboplatin) sa i bez prethodnih kardiovaskularnih oboljenja i utvrditi učestalost pojave kardiotoksičnosti u toku primene protokola docetaxel/cisplatin kao hemioterapije druge linije, u odnosu na primenu protokola gemcitabin/ cisplatin i paclitaxel/carboplatin, kao terapije prve linije. Istraživanjem je obuhvaćeno 270 bolesnika sa citolo&scaron;ki ili patohistolo&scaron;ki dokazanim NSCLC kliničkog stadiju ma III i IV.&nbsp; Dobijeni su rezultati koji ukazuju da je preživljavanje bolesnika u III i IV stadijumu NSCLC koji su imali pojavu kardiotoksičnosti tokom hemioterapije prve i druge linije kraće u odnosu na bolesnike bez pojave kardiotoksičnosti, sa statističkom značajno&scaron;ću nakon prvog, drugog, četvrtog ciklusa hemioterapije i nakon &scaron;est meseci (p=0.004, p=0.020, p=0.030 i p&lt;0.0005. respektivno). Kardiotoksičnost kod bolesnika u III i IV stadijumu NSCLC koji su primali hemioterapiju prve linije prema protokolu gemcitabin/cisplatin se če&scaron;će javila ukoliko su imali prethodne kardiovaskularne bolesti, ali statistička značajnost nije utvrđena. Kardiotoksičnost kod bolesnika u III i IV stadijumu NSCLC koji su primali hemioterapiju prve linije prema protokolu paclita xel/carboplatin se če&scaron;će javila ukoliko su imali prethodne kardiovaskularne bolesti, a statistička značajnost utvrđena prilikom prvog kontrolnog pregleda kod bolesnika u III stadijumu (p=0.037). Kod bolesnika u III i IV stadijumu NSCLC koji su primali hemioterapiju prve linije prema protokolima gemcitabin/cisplatin paclitaxel / carboplatin kardiotoksičnost se če&scaron;će javila ukoliko su imali prethodna kardiovaskularna oboljenja, ali je statistička značajnost ustanovljena samo pri prvom kontrolnom pregledu , (p=0.022). Kod bolesnika koji su primali hemioterapiju druge linije kardiotoksičnost značajno če&scaron;će javila u toku prvog ciklusa hemioterapije (p=0.049) u odnosu&nbsp; na&nbsp; bolesnike&nbsp; koji&nbsp; su&nbsp; primali hemioterapiju&nbsp; prve&nbsp; linije.&nbsp; Kod bolesnika koji su imali prethodne kardiovaskularne bolesti u toku druge linije hemioterapije kardiotoksičnost se statistički značajno če&scaron;će javila u odnosu na prvu liniju hemioterapije u toku četvrtog ciklusa hemioterapije (p=0.020). Uspostavljanje ravnoteže između efektivnosti hemioterapije i rizika od o&scaron;tećenja kardiovaskularnog sistema zahteva blisku saradnju onkologa i kardiologa , sa ciljem kreiranja individualne terapije za svakog bolesnika.</p> / <p>Lung&nbsp; cancer&nbsp; chemotherapy&nbsp; affects&nbsp; the&nbsp; cardiovascular&nbsp; system&nbsp; as&nbsp; well. The research&nbsp; objectives&nbsp; were&nbsp; to&nbsp; establish:&nbsp; the&nbsp; effects&nbsp; of&nbsp; cardiotoxicity&nbsp; on&nbsp; the survival of advanced NSCLC patients;&nbsp; the frequency of cardiotoxicity in the patients&nbsp; treated&nbsp; with&nbsp; the&nbsp; first - line&nbsp; chemotherapy&nbsp; (gemcitabine/cisplatin&nbsp; and paclitaxel/carboplatin),&nbsp;&nbsp; with&nbsp;&nbsp; or&nbsp;&nbsp; without&nbsp;&nbsp; the&nbsp;&nbsp; history&nbsp;&nbsp; of&nbsp;&nbsp; cardiovascular comorbidities, and the frequency of cardiotoxicity registered in the course of the&nbsp; second - line&nbsp; chemotherapy&nbsp; with docetaxel/cisplatin,&nbsp; as&nbsp; compared&nbsp; to&nbsp; the first - line chemotherapy&nbsp; with gemcitabine/cisplatin and paclitaxel/carboplatin.&nbsp;&nbsp;&nbsp; The&nbsp;&nbsp;&nbsp; investigation&nbsp;&nbsp;&nbsp; included&nbsp;&nbsp;&nbsp; 270&nbsp;&nbsp;&nbsp; patients&nbsp;&nbsp;&nbsp; with citologically&nbsp; or histopathologically&nbsp; confirmed&nbsp; NSCLC&nbsp; at&nbsp; the&nbsp; clinical&nbsp; stages III&nbsp; and&nbsp; IV. The&nbsp; obtained&nbsp; research&nbsp; results&nbsp; suggest&nbsp; the&nbsp; patients&nbsp; with&nbsp; stage&nbsp; III and IV NSCLC who developed&nbsp; cardiotoxicity in the course of&nbsp; the first &ndash; and second - line&nbsp;&nbsp; chemotherapy&nbsp;&nbsp; had&nbsp;&nbsp; a&nbsp;&nbsp; shorter&nbsp;&nbsp; survival&nbsp;&nbsp; than&nbsp;&nbsp; those&nbsp;&nbsp; without cardiotoxicity,&nbsp; with&nbsp; the&nbsp; statistical&nbsp; significance&nbsp; registered&nbsp; after&nbsp; the&nbsp; first, second,&nbsp; and&nbsp; fourth&nbsp; chemotherapy&nbsp; course,&nbsp; as&nbsp; well&nbsp; as&nbsp; six&nbsp; months&nbsp;&nbsp;&nbsp; later (p=0.004,&nbsp; p=0.020,&nbsp; p=0.030&nbsp; and&nbsp; p&lt;0.0005&nbsp; respectively). Stage&nbsp; III&nbsp; and&nbsp; IV NSCLC&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; patients&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; receiving&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; first - line&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chemotherapy&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with gemcitabine/cisplatin developed cardiotoxicity more frequently if they had a former history of cardiovascular diseases, but with no statistical significance registered. Stage&nbsp; III and IV NSCLC patients on the&nbsp; first - line&nbsp; chemotherapy protocol&nbsp;&nbsp;&nbsp; with&nbsp;&nbsp;&nbsp; paclitaxel/carboplatin&nbsp;&nbsp;&nbsp; developed&nbsp;&nbsp;&nbsp; cardiotoxicity&nbsp;&nbsp;&nbsp; more frequently&nbsp; if&nbsp; they&nbsp; had&nbsp; a&nbsp; former&nbsp; history&nbsp; of&nbsp; cardiovascular&nbsp; diseases,&nbsp; and&nbsp; the&nbsp; statistical significance was registered at the first control examination in stage III&nbsp; NSCLC&nbsp; patients&nbsp; (p=0.037).&nbsp; Stage III&nbsp; and&nbsp; IV&nbsp; NSCLC&nbsp; patients&nbsp; receiving the&nbsp;&nbsp; first-line&nbsp;&nbsp; chemotherapy&nbsp;&nbsp; protocols&nbsp;&nbsp; with&nbsp;&nbsp; gemcitabine/cisplatin&nbsp;&nbsp; and paclitaxel/carboplatin&nbsp; developed&nbsp; cardiotoxicity&nbsp; more&nbsp; frequently&nbsp; if&nbsp; they&nbsp; had former cardiovascular diseases, but the statistical significance was registered at&nbsp;&nbsp; the&nbsp;&nbsp; first&nbsp;&nbsp; control&nbsp;&nbsp; examination&nbsp;&nbsp; only, one&nbsp;&nbsp; month&nbsp;&nbsp; after&nbsp;&nbsp; chemotherapy application (p=0.022). The&nbsp; patients receiving the&nbsp; second - line&nbsp; chemotherapy developed&nbsp; cardiotoxicity&nbsp; much&nbsp; more&nbsp; often&nbsp; during&nbsp; the&nbsp; first&nbsp; chemotherapy course (p=0.049),&nbsp;&nbsp; as&nbsp;&nbsp; compared&nbsp;&nbsp; to&nbsp;&nbsp; the&nbsp;&nbsp; patiens&nbsp;&nbsp; receiving&nbsp;&nbsp; the&nbsp;&nbsp; first - line chemotherapy.&nbsp; Among&nbsp; the&nbsp; patients&nbsp; with&nbsp; a&nbsp; former&nbsp; history&nbsp; of&nbsp; cardiovascular diseases,&nbsp;&nbsp;&nbsp; those&nbsp;&nbsp;&nbsp; receiving&nbsp;&nbsp;&nbsp; the&nbsp;&nbsp;&nbsp; second &ndash; line&nbsp;&nbsp;&nbsp; chemotherapy&nbsp;&nbsp;&nbsp; developed cardiotoxicity&nbsp; during&nbsp; the&nbsp; fourth&nbsp; chemotherapy&nbsp; course&nbsp; significanly&nbsp; more freequently&nbsp;&nbsp; than&nbsp;&nbsp; the&nbsp;&nbsp; patients&nbsp;&nbsp; on&nbsp;&nbsp; the&nbsp;&nbsp; same&nbsp;&nbsp; course&nbsp;&nbsp; of&nbsp;&nbsp; the&nbsp;&nbsp; first-line chemotherapy&nbsp; (p=0.020). To&nbsp; achieve&nbsp; the&nbsp; balance&nbsp; between&nbsp; chemotherapy efficacy&nbsp; and&nbsp; the&nbsp; risk&nbsp; of&nbsp; the&nbsp; cardiovascular&nbsp; system&nbsp; damage&nbsp; requires&nbsp; a&nbsp; close cooperation of an oncologist and a cardiologist, aimed at designing a unique, individual therapy for each patient.</p>

<p><!--[if gte mso 9]><xml> <w:WordDocument> <w:View>Normal</w:View> <w:Zoom>0</w:Zoom> <w:TrackMoves/> <w:TrackFormatting/> <w:PunctuationKerning/> <w:ValidateAgainstSchemas/> <w:SaveIfXMLInvalid>false</w:SaveIfXMLInvalid> <w:IgnoreMixedContent>false</w:IgnoreMixedContent> <w:AlwaysShowPlaceholderText>false</w:AlwaysShowPlaceholderText> <w:DoNotPromoteQF/> <w:LidThemeOther>EN-US</w:LidThemeOther> <w:LidThemeAsian>X-NONE</w:LidThemeAsian> <w:LidThemeComplexScript>X-NONE</w:LidThemeComplexScript> <w:Compatibility> <w:BreakWrappedTables/> <w:SnapToGridInCell/> <w:WrapTextWithPunct/> <w:UseAsianBreakRules/> <w:DontGrowAutofit/> <w:SplitPgBreakAndParaMark/> <w:DontVertAlignCellWithSp/> <w:DontBreakConstrainedForcedTables/> <w:DontVertAlignInTxbx/> <w:Word11KerningPairs/> <w:CachedColBalance/> </w:Compatibility> <w:BrowserLevel>MicrosoftInternetExplorer4</w:BrowserLevel> <m:mathPr> <m:mathFont m:val="Cambria Math"/> <m:brkBin m:val="before"/> <m:brkBinSub m:val="&#45;-"/> <m:smallFrac m:val="off"/> <m:dispDef/> <m:lMargin m:val="0"/> <m:rMargin m:val="0"/> <m:defJc m:val="centerGroup"/> <m:wrapIndent m:val="1440"/> <m:intLim m:val="subSup"/> <m:naryLim m:val="undOvr"/> </m:mathPr></w:WordDocument></xml><![endif]--></p><p><!--[if gte mso 9]><xml> <w:LatentStyles DefLockedState="false" DefUnhideWhenUsed="true" DefSemiHidden="true" DefQFormat="false" DefPriority="99" LatentStyleCount="267"> <w:LsdException Locked="false" Priority="0" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Normal"/> <w:LsdException Locked="false" Priority="9" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="heading 1"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 2"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 3"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 4"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 5"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 6"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 7"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 8"/> <w:LsdException Locked="false" Priority="9" QFormat="true" Name="heading 9"/> <w:LsdException Locked="false" Priority="39" Name="toc 1"/> <w:LsdException Locked="false" Priority="39" Name="toc 2"/> <w:LsdException Locked="false" Priority="39" Name="toc 3"/> <w:LsdException Locked="false" Priority="39" Name="toc 4"/> <w:LsdException Locked="false" Priority="39" Name="toc 5"/> <w:LsdException Locked="false" Priority="39" Name="toc 6"/> <w:LsdException Locked="false" Priority="39" Name="toc 7"/> <w:LsdException Locked="false" Priority="39" Name="toc 8"/> <w:LsdException Locked="false" Priority="39" Name="toc 9"/> <w:LsdException Locked="false" Priority="35" QFormat="true" Name="caption"/> <w:LsdException Locked="false" Priority="10" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Title"/> <w:LsdException Locked="false" Priority="1" Name="Default Paragraph Font"/> <w:LsdException Locked="false" Priority="11" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtitle"/> <w:LsdException Locked="false" Priority="22" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Strong"/> <w:LsdException Locked="false" Priority="20" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Emphasis"/> <w:LsdException Locked="false" Priority="59" SemiHidden="false" UnhideWhenUsed="false" Name="Table Grid"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Placeholder Text"/> <w:LsdException Locked="false" Priority="1" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="No Spacing"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 1"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 1"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 1"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 1"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 1"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 1"/> <w:LsdException Locked="false" UnhideWhenUsed="false" Name="Revision"/> <w:LsdException Locked="false" Priority="34" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="List Paragraph"/> <w:LsdException Locked="false" Priority="29" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Quote"/> <w:LsdException Locked="false" Priority="30" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Quote"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 1"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 1"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 1"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 1"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 1"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 1"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 1"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 1"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 2"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 2"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 2"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 2"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 2"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 2"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 2"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 2"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 2"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 2"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 2"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 2"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 2"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 2"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 3"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 3"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 3"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 3"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 3"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 3"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 3"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 3"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 3"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 3"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 3"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 3"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 3"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 3"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 4"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 4"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 4"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 4"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 4"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 4"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 4"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 4"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 4"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 4"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 4"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 4"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 4"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 4"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 5"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 5"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 5"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 5"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 5"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 5"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 5"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 5"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 5"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 5"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 5"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 5"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 5"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 5"/> <w:LsdException Locked="false" Priority="60" SemiHidden="false" UnhideWhenUsed="false" Name="Light Shading Accent 6"/> <w:LsdException Locked="false" Priority="61" SemiHidden="false" UnhideWhenUsed="false" Name="Light List Accent 6"/> <w:LsdException Locked="false" Priority="62" SemiHidden="false" UnhideWhenUsed="false" Name="Light Grid Accent 6"/> <w:LsdException Locked="false" Priority="63" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 1 Accent 6"/> <w:LsdException Locked="false" Priority="64" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Shading 2 Accent 6"/> <w:LsdException Locked="false" Priority="65" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 1 Accent 6"/> <w:LsdException Locked="false" Priority="66" SemiHidden="false" UnhideWhenUsed="false" Name="Medium List 2 Accent 6"/> <w:LsdException Locked="false" Priority="67" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 1 Accent 6"/> <w:LsdException Locked="false" Priority="68" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 2 Accent 6"/> <w:LsdException Locked="false" Priority="69" SemiHidden="false" UnhideWhenUsed="false" Name="Medium Grid 3 Accent 6"/> <w:LsdException Locked="false" Priority="70" SemiHidden="false" UnhideWhenUsed="false" Name="Dark List Accent 6"/> <w:LsdException Locked="false" Priority="71" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Shading Accent 6"/> <w:LsdException Locked="false" Priority="72" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful List Accent 6"/> <w:LsdException Locked="false" Priority="73" SemiHidden="false" UnhideWhenUsed="false" Name="Colorful Grid Accent 6"/> <w:LsdException Locked="false" Priority="19" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Emphasis"/> <w:LsdException Locked="false" Priority="21" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Emphasis"/> <w:LsdException Locked="false" Priority="31" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Subtle Reference"/> <w:LsdException Locked="false" Priority="32" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Intense Reference"/> <w:LsdException Locked="false" Priority="33" SemiHidden="false" UnhideWhenUsed="false" QFormat="true" Name="Book Title"/> <w:LsdException Locked="false" Priority="37" Name="Bibliography"/> <w:LsdException Locked="false" Priority="39" QFormat="true" Name="TOC Heading"/> </w:LatentStyles></xml><![endif]--><!--[if gte mso 10]><style> /* Style Definitions */ table.MsoNormalTable{mso-style-name:"Table Normal";mso-tstyle-rowband-size:0;mso-tstyle-colband-size:0;mso-style-noshow:yes;mso-style-priority:99;mso-style-qformat:yes;mso-style-parent:"";mso-padding-alt:0in 5.4pt 0in 5.4pt;mso-para-margin-top:0in;mso-para-margin-right:0in;mso-para-margin-bottom:10.0pt;mso-para-margin-left:0in;line-height:115%;mso-pagination:widow-orphan;font-size:11.0pt;font-family:"Calibri","sans-serif";mso-ascii-font-family:Calibri;mso-ascii-theme-font:minor-latin;mso-fareast-font-family:"Times New Roman";mso-fareast-theme-font:minor-fareast;mso-hansi-font-family:Calibri;mso-hansi-theme-font:minor-latin;}</style><![endif]--></p><p class="MsoNormal" style="text-align:justify">Uvod: Aristolohična kiselina I je nefrotoksična i kancerogena supstanca koja je odgovorna za nefropatiju koja nastaje usled kori&scaron;ćenja herbalnih preparata i čajeva za mr&scaron;avljenje. S obzirom da se ova supstanca može naći u korovskim biljkama, smatra se jednim od glavnih ekotoksikolo&scaron;kih uzroka za nastanak balkanske endemske nefropatije čiji definitivan uzrok jo&scaron; uvek nije otkriven. Toksičnost ove supstance je dokazana na brojnim animalnim modelima, međutim mehanizmi koji dovode do o&scaron;tećenja bubrežnog parenhima jo&scaron; u potpunosti nisu razja&scaron;njeni.<span style="mso-spacerun:yes">&nbsp; </span>Cilj: Doktorska disertacija je koncipirana sa ciljem da se utvrdi uticaj toksičnog jedinjenja aristolohične kiseline I na histopatolo&scaron;ke i imunohistohemijske karakteristike tubulointersticijuma i glomerula bubrega kod mi&scaron;eva, kao i na biohemijske parametre krvi i urina koji ukazuju na o&scaron;tećenje bubrega. Materijal i metode: U ekperimentu je kori&scaron;ćeno 64 mi&scaron;a soja NMRI koji su podeljeni u tri grupe: eksperimentalna grupa (n=32) koja je dobijala aristolohičnu kiselinu I rastvorenu u polietilen glikolu (2,5% PEG 400) u dozi od 10 mg/kg telesne mase, negativna kontrolna grupa koja je dobijala 2,5% PEG 400 (n=16) i kontrolna grupa koja je dobijala fiziolo&scaron;ki rastovor (n=16). Sve životinje su tretirane intraperitonealno svakodnevno tokom sedam dana. Tokom eksperimenta 8., 17., 29. i 59. dana sakupljan je dvadesetčetvoročasovni urin 8 životinja iz eksperimentalne grupe, 4 životinje iz negativne kontrolne i 4 životinje iz kontrolne grupe. Životinje su žrtvovane 9., 18., 30. i 60. dana, uzeta im je krv, dok su bubrezi posebno odvojeni radi histopatolo&scaron;ke analize. Na bubrežnom tkivu sprovedene su histohemijske, imunohistohemijske i morfometrijske analize, dok su na uzorcima seruma i urina sprovedene biohemijske analize. Dobijeni rezultati su testirani adekvatnim statističkim metodama i prikazani su tabelarno i grafički. Rezultati: Nefrotoksin aristolohična kiselina I nakon 7 dana aplikacije izaziva značajno o&scaron;tećenje bubrežnog parenhima. Pri aplikaciji 2,5% PEG 400 i fiziolo&scaron;kog rastvora ne dolazi do vidljivog o&scaron;tećenja bubrežnog parenhima. Histopatolo&scaron;ku sliku u ranoj fazi eksperimenta (9. i 18. dan) karakteri&scaron;e akutna tubulska nekroza proksimalnih tubula. U kasnijoj fazi (30. i 60. dana) uočava se histopatolo&scaron;ka slika hroničnog intersticijalnog nefritisa sa obilnim mononuklearnim ćelijskim infiltratima limfocitnog porekla kao i postojanje blage intersticijalne fibroze. Kod eksperimentalnih životinja je morfometrijskim metodama utvrđen veći stepen bubrežnog o&scaron;tećenja tubulointersticijuma i smanjen broj podocita u glomerulu u odnosu na kontrolne grupe. Biohemijske analize kod većine eksperimentalnih životinja su pokazale veće koncentracije serumske uree nego kod kontrolnih grupa. Takođe je dokazana albuminurija u kasnijoj fazi eksperimenta koja je veća kod životinja izloženih aristolohičnoj kiselini I nego kod životinja iz kontrolnih grupa. Zaključak: Kori&scaron;ćenjem morfometrijskih metoda u okviru histopatolo&scaron;kih i imunohistohemijskih ispitivanja, uz adekvatne biohemijske analize, može se zaključiti da je aristolohična kiselina I izuzetno nefrotoksično jedinjenje koje izaziva izrazite<span style="mso-spacerun:yes">&nbsp; </span>promene tubulointersticijuma i glomerula. Podaci ovog istraživanja predstavljaju polaznu osnovu za dalja istraživanja dijagnostike u ranoj fazi nefropatija izazvanih aristolohičnim kiselinama.<span style="mso-spacerun:yes">&nbsp; </span></p> / <p>Introduction: Aristolochic acid I is a nephrotoxic and carcinogenic substance responsible for nephropathy caused by the use of herbal preparations and teas for slimminng regimen. Since this substance can be found in plants, it is considered one of the major ecotoxicological causes for the emergence of balkan endemic nephropathy whose definitive cause has not yet been revealed. The toxicity of this substance has been proven on numerous animal models, but pathophysiological mechanisms of kidney injury still remain unclear. Aim: The doctoral dissertation was designed to determine the influence of aristolochic acid on the histopathological and immunohistochemical characteristics of tubulointerstitium and glomerulus in mice, as well as the biochemical parameters of blood and urine that indicate kidney injury. Material and methods: For this study, 64 mouse of NMRI strain is used. They are divided into three groups: an experimental group (n=32) that received aristolochic acid I dissolved in polyethylene glycol (2.5% PEG 400) at a dose of 10 mg/kg of body weight, a negative control group that received 2.5% PEG 400 (n=16) and a control group that received only saline (n=16). All animals were treated intraperitoneally daily for seven days. During the experiment on the 8th, 17th, 29th and 59th day, twenty-four-hour urine was collected from 8 animals from the experimental group, 4 animals from the negative control and 4 animals from the control group. Animals were sacrificed on the 9th, 18th, 30th and 60th days, their blood was taken, while the kidneys were taken for histopathological analysis. Histochemical, immunohistochemical and morphometric analyzes were performed on renal tissue, while biochemical analyzes were performed on serum and urine samples. Obtained results were tested with adequate statistical methods and presented in a tables and graphs. Results: After 7 days of application nefrotoxin aristolochic acid I causes significant kidney injury. After application of 2.5% PEG 400 and saline, there was no visible damage to kidney parenchyma. Histopathological changes at the early stage of the experiment (9th and 18th day) were characterized by acute tubular necrosis of proximal tubules. At a later stage (30th and 60th day), chronic interstitial nephritis was observed in kidneys, with abundant mononuclear cell infiltrates in interstitium and presence of mild interstitial fibrosis. In experimental animals, a higher tubulointerstitial score of kidney injury and a decrease in the number of the podocytes in glomerulus were determined by morphometric methods, compared to the control groups. Biochemical analyzes in most experimental animals showed higher blood urea nitrogen concentrations than in control groups. High concentration of albumin in urine can be found in later stages of the experiment, and those concentrations were higher in animals exposed to aristolochic acid I than in animals from control groups.&nbsp; Conclusion: Using morphometric, histopathological and immunohistochemical methods, with adequate biochemical analysis, aristolochic acid I is proven to be an extremely nephrotoxic compound that causes drastic changes in tubulointerstitium and glomeruli of kidney parenhyma. Data from this study can be used for further research into early diagnosis of aristolochic acid nephropathy.</p>

<p>U eksperimantalnom postupku disertacije mi&scaron;evi NMRI soja su tretirani infuzom biljke Aristolochia clematitis. Sasu&scaron;eni listovi, grane i plodovi biljke potopljeni su u ključalu vodu i ostavljeni 3-5 sati da stoje, a potom su profiltrirani kroz filter papir. Pravljen je rastvor biljke/vode od 10g/ 1000ml (1%), 20g/ 1000ml (2%) i 40g/ 1000ml (4%). Različite koncentracije infuza su date mi&scaron;evima da piju u neograničenoj količini u periodu od 7 nedelja. Tako su formirane tri ispitne grupe, prva koja je primala 1% infuz, druga 2% infuz i treća 4% infuz i kontrolna grupa koja je dobijala samo vodu da pije. U svakoj grupi je bilo 20 životinja. Tako je razvijen animalni model hronične toksičnosti. Na kraju eksperimenta je urađena patohistolo&scaron;ka analiza bubrega, makroskopski pregled organa i merenje diureze tokom trajanja eksperimenta. Urađena je kompletna analiza urina koja podrazumeva utvrđivanje: boje, izgleda, pH, specifične težine, proteina i sedimenta urina. Analize urina ponavljane su na svakih 7 dana u toku 7 nedelja istraživanja. Na kraju eksperimenta urađena je analiza biohemijskih parametara (glukoza, urea, kreatinin, mokraćna kiselina, ukupni bilirubin, direktni bilirubin, ukupni tj. totalni proteini, natrijum i kalijum) i analiza kompletne krvne slike. Utvrđeno je da je Aristolochia clematitis izrazito nefrotoksična biljka. Utvrđene su patohistolo&scaron;ke promene tubula i intersitcijuma NMRI mi&scaron;a, koje su bile najveće u ispitnoj grupi koja je primala najaču dozu. Ustanovljene&nbsp; patohistolo&scaron;ke promene su slične opisanim patohistolo&scaron;kim promenama tubulointersticijuma bolesnika obolelih od Balkanske endemske nefropatije. Nije ustanovljeno postojanja karcinoma gornjeg urotrakta. Makroskopskim pregledom prilikom obdukcije eksperimentalnih životinja nisu ustanovljene značajnije promene bubrega. Do&scaron;lo je prvo do izrazitog porasta diureze u prvoj, odnosno drugoj nedelji praćenja, kod druge i treće eksperimentalne grupe, da bi nakon 7 nedelja istaživanja diureza u svim ispitnim grupama bila manja od kontrolne grupe. Postoji porast ureje na kraju istraživanja, koji je dvostruko veći u trećoj eksperimentalnoj grupi u odnosu na kontrolnu. Postoji izrazit pad mokraćne kiseline na kraju istraživanja kod eksperimentalne grupe 3. Postoji izrazit pad granulocita u leukocitarnoj formuli u svim ispitnim grupama, a najveći je u trećoj ispitnoj grupi. Kako je do&scaron;lo do pada relativnih vrednosti granulocita, tako je do&scaron;lo do porasta relativnih vrednosti limfocita u prvoj i drugoj ispitnoj grupi. U trećoj ispitnoj grupi je pad granulocita praćen izrazito velikim povećanjem relativnog broja bazofilnih granulocita. Postoji značajan pad specifične težine urina na kraju istraživanja u drugoj i trećoj eksperimentalnoj grupi. Proteinurija je bila čest nalaz svim eksperimentalnim grupama, dok je bila odsutna ili samo u tragu u kontrolnoj grupi. Na kraju eksperimenta je utvrđen znatni porast broja kristala fosfata u eksperimentalnim grupama. Cilindri su se pojavljivali samo u nalazu urina u trećoj ispitnoj grupi. Najveći broj promena urina je utvrđen u trećoj eksperimentlanoj grupi.</p> / <p>In the experimental procedure of dissertation, NMRI strain mice were treated with infusion of plants Aristolochia clematitis. Dried leaves, branches and fruit plants are submerged in boiling water and left to stand for 3-5 hours, and then filtered through filter paper. It was made a solution of the plant / water of 10g / 1000ml (1%), 20g / 1000ml (2%) and 40g / 1000ml (4%). Different concentrations of infusions were given to mice to drink an unlimited amount for a period of 7 weeks. So we formed the three test groups, the first who received 1% infusion, the second received 2% infusion and third received 4% infusion and a control group that received only water to drink. In each group there were 20 animals. Thus, developed an animal model of chronic toxicity. At the end of the experiment was performed histopathological analysis of kidneys, macroscopic examination of organs and measuring urine output during the experiment. We performed a complete analysis of urine, which is the determination of: color, appearance, pH, specific gravity, protein and urine sediment. Urinalysis were repeated every 7 days during the 7 weeks of the study. At the end of the experiment were analyzed for biochemical parameters (glucose, urea, creatinine, uric acid, total bilirubin, direct bilirubin, total proteins, sodium and potassium) and analysis of the complete blood count. It has been found that Aristolochia clematitis is extremely nephrotoxic plant. Identified histopathological changes of tubules and interstitium of NMRI mouse, which were the biggest in the test group receiving biggest dose. Established histopathological changes are similar to those described by pathological changes of tubulointerstitial injury of patients with Balkan endemic nephropathy. Not established the existence of cancer of the upper urinary tract. Macroscopic examination at autopsy of experimental animals, did not determine significant changes in the kidneys. There is first an enormous increase in diuresis in the first and second week of follow-up, in the second and third experimental groups retrospectively, that after 7 weeks of research, diuresis in all test groups was lower than the control group. There is an increase of urea at the end of the research, which is twice higher in the third experimental group compared to the control. There is a marked decrease in uric acid at the end of the research in the experimental group 3. There is a marked decrease in granulocytes in the leukocyte formula in all test groups, and the highest in the third test group. As the decline in the relative values of granulocytes, so there has been a rise in the relative values of lymphocite in the first and second test group. In the third test group, granulocyte drop was accompanied by a extremely large increase in the relative number of basophils. There is a significant drop in specific gravity of urine at the end of the research in the second and third experimental group. Proteinuria is a common finding to all experimental groups, while it was absent or only in traces in the control group. At the end of the experiment was determined to increase significantly the number of phosphate crystals in the experimental groups. The cylinders have appeared only in the urine in the third test group. The greatest number of changes in the urine is determined in the third experimental group.</p>

<p>Akrilamid je toksična hemijska supstanca koja ima vrlo &scaron;iroku primenu u hemijskoj industriji, a 2002. godine otkriveno je njegovo prisustvo u namirnicima bogatim skrobom koje se pripremaju na visokim temperaturama. U poslednjh desetak godina primećen je veliki porast gastrointestinalnih tegoba u ljudskoj populaciji. Cilj istraživanja bio je ispitati patohistolo&scaron;ke promene u tkivu želuca pacova soja Wistar izazvanih peroralnim aplikovanjem akrilamida i na taj način povući paralelu sa mogućim gastrointestinalnim tegobama nastalim kao posledica konzumiranja hrane bogate akrilamidom. U istraživanju je ispitivano 6 grupa od po 5 eksperimentalnih životinja (pacovi soja Wistar). Dve kontrolne grupe kojima je peroralno aplikovana destilovana voda i koje su žrtvovane posle 24h i 72h; dve eksperimentalne kojima je peroralno aplikovan akrilamid u dnevnoj dozi od 25 mg/kg i koje su žrtvovane posle 24h i 72h; dve eksperimentalne grupe kojima je peroralno aplikovan akrilamid u dnevnoj dozi od 50 mg/kg i koje su žrtvovane posle 24h i 72h. Na histolo&scaron;kom materijalu tkiva želuca primenjena je kvalitativna histolo&scaron;ka analiza pod svetlosnim mikroskopom, semikvantitativna procena tipa mucina u epitelnim ćelijama sluznice želuca, prisustvo limfocita i granulocita u sluznici želuca, stereolo&scaron;ka merenja pojedinih kompartmana zida želuca, linearna merenja broja i veličine ganglijskih ćelija u Maissner-ovom i Auerbach-ovom nervnom pleksusu, kao i broj mastocita u lamini propriji sluznice i podsluznici želuca. Dobijene vrednosti merenih parametara su potom statistički obrađene. Nastale promene na tkivu želuca pacova soja Wistar se ogledaju u vidu blagog direktnog o&scaron;tećenja povr&scaron;nog epitela sa propratnom blagom inflamatornom reakcijom i blagom degranulacijom mastocita. U Maissner-ovom i Auerbach-ovom nervnom pleksusu su smanjene volumenske gustine nervnih vlakana i ganglijskih ćelija, kao i broj i veličina ganglijskih ćelija. Direktno toksično delovanje na epitel dovodi do posledične obnove epitela, te je potvrđeno prisustvo nezrelijih oblika mukoproduktivnih ćelija koje sadrže kisele, AB pozitivne mucine. Ispitani inflamatorni i degenerativni parametri pokazuju pozitivnu korelaciju u odnosu na dozu i/ili dužinu ekspozicije akrilamidu. Primena akrilamida peroralno pokazala je da postoje patohistolo&scaron;ke promene na tkivu želuca u vidu direktnog toksičnog o&scaron;tećenja epitela, inflamatorne reakcije i o&scaron;tećenja nervnih pleksusa. Poznavanjem mehanizma delovanja ove toksične materije moguće je primeniti adekvatnu prevenciju u ishrani i izvr&scaron;iti odgovarajući izbor terapijskih metoda.</p> / <p>Acrylamide is a toxic chemical substance with wide implementation in chemical industry. In 2002 it was discovered the presence of acrylamide in foods rich in starch which are prepared at high temperatures. In the last ten years there is a large increase in gastrointestinal illnesses in human population. The aim of this study was to investigate the histopathological changes in the gastric tissue in Wistar rats induced with injection of oral acrylamide and thus draw a parallel with possible gastrointestinal problems arising as a result of the consumption of foods rich in acrylamide. The research was carried out 6 groups of 5 experimental animals (Wistar rats). Two control groups that are orally concomitant application of distilled water and which were sacrificed after 24h and 72h; two experimental groups which are orally administrated acrylamide in a daily dose of 25 mg / kg and that were sacrificed after 24h and 72h; two experimental groups which were orally administrated acrylamide in a daily dose of 50 mg / kg and that were sacrificed after 24h and 72h. On histological gastric tissue material is applied qualitative histological analysis by light microscopy, semi-quantitative assessment of the type of mucin in epithelial cells of the stomach lining, the presence of lymphocytes and granulocytes in gastric mucosa, stereological measurements of individual compartments of the stomach wall, linear measuring the number and size of ganglion cells in the Maissner and Auerbach&#39;s nerve plexus, and the number of mast cells in the lamina propria of the mucosa and in the submucosis of the stomach. Obtained values of measured parameters were statistically processed. Histological changes in the stomach tissue of Wistar rats are seen as a direct slight damage of the surface epithelium, with accompanynig mild inflammatory reaction and the degranulation of mast cells. The Meissner&#39;s and Auerbach&#39;s nerve plexus decreased volume density of nerve fibers and ganglion cells, as well as the number and size of the ganglion cells. Directly toxic effect on epithelium leads to the result of the reconstruction of the epithelium, which is confirmed by the presence of immature form of mucoproductive cells which contain acid, AB positive mucins. Examined inflammatory and degenerative parameters show a positive correlation with respect to dose and / or a time of exposition to acrylamide. Acrylamide oral application revealed that there are histologic changes in the stomach tissue in the form of a direct toxic damage to the epithelium, inflammatory reaction and damage to the nerve plexus. Knowing the mechanism of action of these toxic substances allows to apply adequate prevention in nutrition and make an appropriate choice of therapeutic methods.</p>

<p>Ispitana je direktna i indirektna fotoliza alprazolama (ALP) i amitriptilina (AMI)<br />primenom UV, vidljivog&nbsp; i simuliranog sunčevog zračenja (SSZ). Takođe, praćena je stabilnost vodenih rastvora ALP i AMI u mraku.&nbsp; U okviru ispitivanja fotokatalitičke&nbsp; razgradnje ALP,ispitana je efikasnost ZnO i TiO_2&nbsp;Degussa P25 primenom UV i SSZ.&nbsp; Takođe, proučavan je&nbsp; utica jmasene koncentracije fotokatalizatora, pH, kao i<br />uticaj hvatača radikala/&scaron;upljina&nbsp; i elektron-akceptora.&nbsp; Praćen je stepen mineralizacije<br />merenjem ukupnog organskog ugljenika i primenom&nbsp; jonske hromatografije. Takođe,<br />detaljno su ispitani reakcioni intermedijeri.&nbsp; Dalje,ispitano&nbsp; je ponovno kori&scaron;ćenje ZnO u tri uzastopna procesa razgradnje ALP. U cilju praćenja citotoksičnosti ALP, ispitan je&nbsp; in vitro rast dve ćelijske linije: Neuro-2a i MRC-5. Zatim,proučavana je efikasnost sintetisanih ZnO (ZnO modifikovani mlevenjem i kalcinacijom, ZnO dopirani jonima Mg(II), ternarni i&nbsp; me&scaron;ani&nbsp; cink-kalaj-oksidi) i TiO₂&nbsp; (anatas&nbsp; TiO₂&nbsp; nedopirani&nbsp; i dopirani La(III)-jonima, brukitni TiO2) nanoprahova u razgradnji ALP primenom UV i SSZ. U okviru fotokatalitičke razgradnje AMI, ispitana&nbsp; je&nbsp; efikasnost&nbsp; razgradnje&nbsp; pri različitim eksperimentalnim uslovima&nbsp; (uticaj vrste fotokatalizatora i zračenja, masene&nbsp; koncentracije fotokatalizatora, početne koncentracije supstrata, uticaj prisustva&nbsp; kako&nbsp; hvatača radikala i &scaron;upljina, tako&nbsp; i elektron-akceptora). Praćen je stepen mineralizacije merenjem ukupnog organskog ugljenika i&nbsp; primenom&nbsp; jonske hromatografije.&nbsp; U cilju praćenja citotoksičnosti&nbsp; AMI, ispitan je&nbsp; in vitro&nbsp; rast četiri ćelijske linije: Neuro-2a, MRC-5, H-4-II-E i HT-29.&nbsp; Zatim, proučavana je efikasnost sintetisanih TiO₂/polianilin nanokompozitnih prahova, kao i&nbsp; prevlaka&nbsp; čistog TiO_2&nbsp;i WO₃/TiO₂&nbsp; u razgradnji AMI primenom UV i SSZ. Takođe, ispitan je uticaj&nbsp; strukture&nbsp; supstrata&nbsp; na efikasnost&nbsp; fotokatalitičke razgradnje kroz ispitivanje&nbsp; efikasnosti sintetisanih TiO₂&nbsp; nanoprahova dopiranih jonima W(VI), zatim me&scaron;anih&nbsp; cink-kalaj-oksid&nbsp; nanoprahova, kao i&nbsp; indijum-cink-oksid nanoprahova primenom UV i SSZ.</p> / <p>Direct and indirect photolysis of alprazolam (ALP) and amitriptyline (AMI) were studied using UV, visible,&nbsp; and simulated solar irradiation (SSI). Also, the stability of the ALP and AMI aqueous solutions in the dark were monitored. Photocatalytic degradation of ALP was studied in&nbsp; the&nbsp; presence of&nbsp; ZnO and TiO₂ Degussa&nbsp; P25&nbsp; using UV and SSI. Also, the influence of the photocatalyst&nbsp; loading, pH, as well as the influence of the radical&nbsp; and&nbsp; holes scavengers&nbsp; and electron acceptors&nbsp; were studied. The&nbsp; degree of mineralization was monitored by measuring&nbsp; of&nbsp; total organic carbon and&nbsp; using&nbsp; ion chromatography. Also, reaction intermediates were examined in detail. Further, reusabillity&nbsp; of ZnO was investigated in three consecutive degradation processes of ALP. In order to&nbsp; get insight into the&nbsp; cytotoxicity of the ALP&nbsp; and intermediates formed during photocatalytic degradation, their influence on the growth of two cell lines: Neuro-2a and MRC-5 were investigated. Then, the efficacy of synthesized ZnO (ZnO modified with milling&nbsp; and calcination, ZnO doped with Mg(II) ions, ternary and coupled binary&nbsp; tin-zinc-oxide) and TiO₂&nbsp; (anatase&nbsp; TiO₂&nbsp; undoped and&nbsp; doped&nbsp; with&nbsp; La(III) ions&nbsp; and&nbsp; brookite TiO₂) nanopowders in ALPdegradation using UV and&nbsp; SSI&nbsp; were investigated. Within the photocatalytic degradation of AMI, the&nbsp; degradation efficiency under different experimental conditions was studies (influence of the photocatalyst and irradiation type, photocatalyst&nbsp; loading, initial&nbsp; substrate concentration, the effect of the presence of radical and&nbsp; holes scavengers, and electron acceptors). The degree of mineralization was monitored by measuring&nbsp; of&nbsp; total organiccarbon and&nbsp; using&nbsp; ion chromatography.&nbsp; In order to&nbsp; study&nbsp; the cytotoxicity of AMI&nbsp; and degradation intermediates, their influence on the&nbsp; growth of four cell lines: Neuro-2a, MRC-5, H-4-II-E,&nbsp; and HT-29&nbsp; were investigated. Then, the efficacy of synthesized TiO2/polyaniline nanocomposite powders, as well as photocatalysts of pure TiO₂&nbsp; and WO₃/TiO₂&nbsp; in the form&nbsp; of&nbsp; films&nbsp;&nbsp; in AMI degradation using UV and SSI were studied. In addition, the effect of the&nbsp; substrate&nbsp; structure on the efficiency of photocatalytic degradation was studied by testing the activity&nbsp; of synthesized TiO_2&nbsp; nanopowders doped with W(VI)&nbsp; ions, then&nbsp; coupled binary tin-zinc- oxide&nbsp; nanopowders, as well as coupled binary&nbsp; indium-zinc- oxide nanopowders using UV and SSI.</p>

<p>Ispitana je direktna i indirektna razgradnja odabranih&nbsp; &beta;-blokatora (metoprolol- tartarata, MET i propranolol-hidrohlorida, PRO) kao i diuretika (hidrohlortiazida, HCTZ) i njegovog stabilnog intermedijera hidrolize 4-amino-6-hlor-1,3-benzendisulfonamida (ABSA). Praćena je i kinetika razgradnje direktnom i indirektnom fotolizom uz primenu UVA, UVC, sunčevog i simuliranog sunčevog zračenja (SSZ). Najpre je ispitana&nbsp; stabilnost MET pod dejstvom SSZ, UVA, UVC, UVA/H₂O_{2 ,} i UVA/&nbsp; BrO₃^-. Dalje je ispitana efikasnost razgradnje MET pod dejstvom O₃i UVC/O_3. Identifikovano je deset intermedijera tokom UVC, O_3&nbsp;i UVC/O₃ razgradnje, pri&nbsp; čemu samo jedan ima značajno vi&scaron;u toksičnost prema algama i bakterijama u odnosu na ostale. Efikasnost fotokatalitičke razgradnje MET je ispitana u TiO₂ suspenzijama sa komercijalnim katalizatorima (Wackherr i Degussa P25). Mehanizam fotokatalitičke razgradnje je detaljno ispitan, pri&nbsp; čemu je identifikovano&nbsp; četrnaest intermedijera. EC₅₀ vrednost MET i njegovih sme&scaron;a nastalih pri fotokatalitičkoj razgradnji su određene na tri ćelijske linije sisara (H-4-II-E, HT-29 i MRC-5). Kako bi se povećala efikasnost&nbsp; rocesa fotokatalitičke razgradnje primenom komercijalnih katalizatora, ispitan je&nbsp; uticaj prisustva elektron-akceptora u suspenziji, pri čemu je upoređen uticaj O₂/H₂O₂, i O₂/ BrO₃^-&nbsp;na mehanizam razgradnje. Na osnovu teorije funkcionala gustine stekao se uvid u promene unutar molekula MET u prisustvu reaktivnih radikala. Takođe, ispitana je efikasnost nedopiranih TiO₂ , kao i dopiranih La(III) nanoprahova sintetisanih sol&minus;gel postupkom, u razgradnji MET. Uticaj temperature &nbsp;kalcinacije na fotokatalitičku efikasnost TiO 2 nanoprahova dopiranih pomoću La(III) &nbsp;ispitana je na supstratima MET i PRO, pri čemu je analiziran i uticaj strukture&nbsp; polaznog jedinjenja na&nbsp; informacija efikasnost fotokatalitičke razgradnje. Rezultati su upoređeni sa nedopiranim TiO₂nanoprahom i TiO₂Degussa P25 (pri pH-vrednosti 9). Pored toga, ispitana je kinetika i toksičnost PRO i njegovih intermedijera nastalih tokom razgradnje sa TiO₂Degussa P25. Ispitan je i uticaj strukture polaznog jedinjenja (MET, HCTZ i ABSA) na fotorazgradnju pod dejstvom&nbsp;UVA, sunčevog i simuliranog sunčevog zračenja, u odsustvu/prisustvu TiO₂ Degussa P25. Takođe, ispitan je i sinergistički efekat MET i ABSA na proces hidrolize, direktne fotolize i fotokatalize sa SSZ/TiO₂Degussa P25. Kako bi se stekao uvid u toksičnost proučavanih sistema, ispitan je njihov uticaj na rast odabranih ćelijskih linija sisara.</p> / <p>Direct and indirect degradation of selected&nbsp; &beta;-blockers (metoprolol tartrate, MET and&nbsp;propranolol hydrochloride, PRO) and also diuretic (hydrochlorothiazide, HCTZ) in &nbsp;addition to its stable hydrolysis intermediate 4-amino-6-chloro-&nbsp;&nbsp; 1,3-benzenedisulfonamide (ABSA) were investigated. The kinetics of their degradation obtained by direct and indirect photolysis under UVA, UVC, sunlight and simulated sunlight irradiation (SSI) have been followed. Firstly, the stability of MET under influence of SSI, UVA, UVC, UVA/H₂O₂ , and UVA/&nbsp; BrO₃^- has been investigated. Further, the efficiency of MET degradation under influence of O₃, and UVC/O₃ has been explored. Ten intermediates have been identified during the UVC, O₃, and UVC/O₃ treatments, while only one intermediate had significantly higher toxicity towards the algae and bacteria in respect to the others. Efficiency of&nbsp; photocatalytic degradation of MET was investigated in TiO₂ suspensions with&nbsp;commercial catalysts (Wackherr and Degussa P25). Mechanism of photocatalytic degradation was investigated in detail according to which fourteen intermediates were identified. EC 50 &nbsp;value of MET and its mixtures formed during the photocatalytic degradation has been determined at three mammalian cell lines (H-4-II-E, HT-29, and MRC-5). In order to improve the efficiency of photocatalytic degradation process applying commercial catalysts, the influence of presence of electron acceptors in suspension has been investigated and the influence of O₂/H₂O_2&nbsp;and O₂/BrO₃^- to the mechanism of degradation has been compared. Based on the density&nbsp; functional theory an insight to the changes within MET molecule in the presence of reactive radicals has been made. Also, the efficiency of bare TiO₂, as well as&nbsp;doped La(III) nanopowders synthesized by sol-gel procedure, in the degradation of&nbsp; MET has been investigated. The influence of calcination temperature on&nbsp; hotocatalytic efficiency of TiO_2&nbsp;nanopowders doped with La(III) has been studied on the MET and&nbsp; PRO substrates, and the influence of structure of the starting compound on the&nbsp; efficiency of &nbsp;photocatalytic degradation had been analyzed. Results have been&nbsp; compared with bare TiO_2&nbsp;nanopowder and TiO₂ Degussa P25 (at pH value of 9). Besides, kinetics and toxicity of PRO and its intermediates formed during the degradation with TiO₂ Degussa P25 have been investigated. The influences of starting compound&rsquo;s structure (MET, HCTZ, and ABSA) to photodegradation under UVA, sunlight and SSI, in the absence/presence of TiO₂ Degussa P25, have been investigated. Also, the synergistic effects of MET and ABSA to the process of&nbsp; hydrolysis, direct photolysis, and photocatalysis with SSI/TiO₂ Degussa P25 have been investigated. In order to get &nbsp;an insight into the toxicity of the studied systems, their influence on the growth of selected mammalian cell lines has been investigated as well.</p>

<p>Ispitana je kinetika i mehanizam fotokatalitičke&nbsp;razgradnje herbicida kvinmeraka i klomazona u prisustvu&nbsp;UV/TiO₂&nbsp; Degussa P25, odnosno piklorama i&nbsp; klopiralida&nbsp;<br />primenom UV/TiO₂&nbsp; Wackherr pri različitim&nbsp;eksperimentalnim uslovima. Praćena je i kinetika&nbsp;razgradnje odabranih herbicida direktnom fotolizom uz&nbsp;primenu sunčevog, UV i vidljivog zračenja, kao i u&nbsp;odsustvu svetlosti. Pored toga, upoređena je efikasnost&nbsp;<br />UV/TiO₂&nbsp; Degussa P25, odnosno UV/TiO₂&nbsp; Wackherr sa&nbsp;vidljivim zračenjem, kao i direktnom fotolizom u&nbsp;prisustvu pomenutih izvora svetlosti.&nbsp; U cilju procene&nbsp;<br />citotoksičnosti klomazona i klopiralida, kao i sme&scaron;e&nbsp;klomazona i klopiralida i njihovih intermedijera nastalih&nbsp;tokom fotokatalitičke razgradnje ispitan je&nbsp; in vitro&nbsp; rast&nbsp;<br />ćelijskih linija&nbsp; MRC-5 i H-4-II-E.&nbsp; Nakon ispitivanja&nbsp;fotokatalitičke razgradnje odabranih herbicida u dvaput&nbsp;destilovanoj vodi, praćena je njihova razgradnja i u&nbsp;prirodnim vodama. Takođe, ispitan je uticaj dodatka&nbsp;hidrogenkarbonata i huminske kiseline na efikasnost&nbsp;razgradnje odabranih herbicida. Fotokatalitička razgradnja&nbsp;klomazona, piklorama i mekopropa je ispitivana i u&nbsp;prisustvu UV/TiO₂&nbsp; nanocevi. Aktivnost katalizatora TiO_2&nbsp;Wackherr&nbsp; i TiO₂&nbsp; nanocevi je upoređena sa TiO₂&nbsp; Degussa&nbsp;P25.</p> / <p>The kinetics and mechanism of photocatalytic degradation&nbsp;of the herbicides quinmerac and clomazone in the&nbsp;presence of UV/TiO₂&nbsp; Degussa P25, and of picloram and&nbsp;clopyralid using UV/TiO₂&nbsp; Wackherr under different&nbsp;experimental conditions were studied. The kinetics of&nbsp;degradation of selected herbicides by direct photolysis&nbsp;using sunlight, UV and visible radiation, and in the&nbsp;absence of light were followed. In addition, the&nbsp;efficiencies of UV/TiO₂&nbsp; Degussa P25 and UV/TiO_2&nbsp;Wackherr &nbsp;were compared with visible radiation and direct&nbsp;photolysis in the presence of the above mentioned light&nbsp;sources. In order to evaluate the cytotoxicity of clomazone&nbsp;<br />and clopyralid alone and in their mixture with&nbsp;intermediates formed during the photocatalytic&nbsp;degradation, in vitro growth of cell lines, MRC-5 and H-4-II-E was followed. After examining&nbsp; the photocatalytic&nbsp;degradation of selected herbicides in double distilled&nbsp;water, their decomposition in natural waters was also&nbsp;followed. Also, the influence of hydrogencarbonate and&nbsp;humic acid addition on the efficiency of degradation of&nbsp;selected herbicides was studied. Photocatalytic&nbsp;degradations of clomazone, picloram and mecoprop were&nbsp;investigated in the presence of UV/TiO_2&nbsp;nanotubes. Activities of the catalysts TiO₂&nbsp; Wackherr and TiO_2&nbsp;nanotubes were compared to TiO₂ Degussa P25.</p>